US 12,109,205 B2
Methods of treating Fabry patients having renal impairment
Jeff Castelli, New Hope, PA (US); and Elfrida Benjamin, Millstone Township, NJ (US)
Assigned to Amicus Therapeutics, Inc., Philadelphia, PA (US)
Filed by Amicus Therapeutics, Inc., Cranbury, NJ (US)
Filed on Oct. 23, 2020, as Appl. No. 17/078,840.
Application 16/678,183 is a division of application No. 16/284,582, filed on Feb. 25, 2019, granted, now 10,471,053, issued on Nov. 12, 2019.
Application 16/284,582 is a division of application No. 15/992,336, filed on May 30, 2018, granted, now 10,251,873, issued on Apr. 9, 2019.
Application 17/078,840 is a continuation of application No. 16/817,881, filed on Mar. 13, 2020, granted, now 10,857,141.
Application 16/817,881 is a continuation of application No. 16/678,183, filed on Nov. 8, 2019, granted, now 10,874,655.
Claims priority of provisional application 62/626,953, filed on Feb. 6, 2018.
Claims priority of provisional application 62/512,458, filed on May 30, 2017.
Prior Publication US 2021/0038583 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/445 (2006.01); A61P 13/12 (2006.01); A61K 9/48 (2006.01)
CPC A61K 31/445 (2013.01) [A61P 13/12 (2018.01); A61K 9/48 (2013.01)] 97 Claims
 
1. A method of treating Fabry disease, the method comprising administering migalastat to a patient in need thereof, wherein the patient has an α-galactosidase A protein comprising a HEK assay amenable mutation selected from the group consisting of: R4M/Y207S, A15T, A15G, F18C, W24G, N34D, G35V, M42I, E48Q, N53D, P60S, F69L, M721, G85S, G85N, G104V, L106F, A108T, D109G, R112G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, G271S/D313Y, W277C, D299E, S304T, D313Y/G411D, I319F, F337S, P343L, G361A, P362T, K391T, G395E and p.T400_S401dup.